Immunotherapy for Third Line Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT04444622. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase IIB Open-Label Study to Assess the Safety and Efficacy of STIMVAX® as Third-line Therapy for Metastatic Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase IIB multi-site, open label study of a next generation immunotherapy for third-line MSI-S metastatic colorectal cancer using an "off-the-shelf", non-genetically manipulated living immune cell product (AlloStim) derived from the blood of healthy donors.
Study identification
- NCT ID
- NCT04444622
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 29 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 11, 2021
- Primary completion
- Mar 30, 2025
- Completion
- Mar 30, 2025
- Last update posted
- Oct 19, 2025
2021 – 2025
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mt. Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Summit Health | Florham Park | New Jersey | 07932 | — |
| Hirschfield Oncology Center | The Bronx | New York | 10469 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Metastatic Colorectal Cancer trials
Other public records listing Metastatic Colorectal Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT06820463: A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer Recruiting
- NCT06202183: Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial Recruiting
- NCT07277322: Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases Recruiting
- NCT07720115: Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer Not yet recruiting
- NCT06412198: A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations Recruiting
- NCT07662031: Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04444622, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2025 · Synced Sep 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04444622 live on ClinicalTrials.gov.